Correvio Pharma Corp. (CORV)
| Market Cap | 27.79M |
| Revenue (ttm) | 32.63M |
| Net Income (ttm) | -35.18M |
| Shares Out | 66.19M |
| EPS (ttm) | -0.80 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Jun 5, 2020 |
| Last Price | $0.420 |
| Previous Close | $0.420 |
| Change ($) | 0.000 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 0.416 - 0.420 |
| Day's Volume | 0 |
| 52-Week Range | 0.210 - 2.790 |
News
NASDAQ: CORV TSX: CORV VANCOUVER, May 21, 2020 /PRNewswire/ - Correvio Pharma Corp. ("Correvio" or the "Company") (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on comm...
Securityholders Approve ADVANZ PHARMA Acquisition NASDAQ: CORV TSX: CORV VANCOUVER, May 15, 2020 /PRNewswire/ - Correvio Pharma Corp. ("Correvio" or the "Company") (NASDAQ: CORV) (TSX: CORV), ...
Correvio (CORV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Correvio (CORV) delivered earnings and revenue surprises of 23.08% and -1.66%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Correvio (CORV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shares of Canadian specialty pharma Correvio Pharma Corp (NASDAQ: CORV) are retreating in reaction to an adverse FDA verdict.
Shares of microcap Correvio Pharma Corp. CORV, +14.57% slid about 12% in premarket trade Tuesday, after the company said it has received a Complete Response Letter from the U.S.
Correvio Pharma Corp. (NASDAQ: CORV) shares were crushed after the firm announced the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) decision...
Shares of Correvio Pharma CORV, +7.69% tumbled 54% in premarket trading after the specialty drugmaker said it was considering a sale of the company or its assets.
Correvio Pharma Corp CORV shares came under selling pressure Friday after a briefing document released ahead of the company's planned Adcom meeting showed that FDA staffers were not convin...
Shares of Correvio Pharma Corp. were halted in advance of a Food and Drug Administration advisory committee meeting for its experimental atrial fibrillation therapy.
Correvio Pharma's (CORV) CEO Mark Corrigan on Q3 2019 Results - Earnings Call Transcript
Correvio Pharma Corp. (CORV) CEO Mark Corrigan on Q2 2019 Results - Earnings Call Transcript
Correvio Pharma Corp. (CORV) CEO Mark Corrigan on Q1 2019 Results - Earnings Call Transcript
About CORV
Correvio Pharma, a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its products comprise Aggrastat (tirofiban hydrochloride), (an intravenous anti-platelet drug for patients with acute coronary syndrome; and Brinavess (vernakalant IV), a novel, atrial-preferential antiarrhythmic agent for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute ... [Read more...]
| Industry Drug Manufacturers—Specialty & Generic | Founded 2018 |
| Stock Exchange NASDAQ | Ticker Symbol CORV |
Financial Performance
In 2019, CORV's revenue was $32.63 million, an increase of 13.81% compared to the previous year's $28.67 million. Losses were -$35.18 million, 112.2% more than in 2018.